Plain-English translation of NCT06557889 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether reducing the number of chemotherapy cycles—from 6 to 4—while combining them with pembrolizumab (an immunotherapy drug) works well for treating advanced head and neck cancer. Researchers want to see if patients can get the same or better results with fewer chemotherapy treatments, which may mean fewer side effects and a better quality of life.
Standard treatment for advanced head and neck cancer typically uses 6 cycles of chemotherapy combined with other drugs. This medication might work just as well with fewer cycles, potentially reducing the burden of treatment on patients while maintaining effectiveness.
You likely qualify if…
You likely don't qualify if…
You would receive 4 cycles of intravenous chemotherapy (platinum-based chemotherapy plus 5-Fluorouracil) combined with pembrolizumab infusions. You would need to attend hospital or clinic visits for treatment administration and regular monitoring, with blood tests and imaging scans to check how well the treatment is working. The study will track your health, side effects, and how your cancer responds over time.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France